Cerus reaffirms $229M-$231M 2026 product revenue as it now expects CE Mark clearance in late 2027
CEO Vivek Jayaraman framed Q3 around growth, innovation, and profitability, saying Cerus is focused on “delivering sustainable double-digit annual growth, advancing clinical and technological innovation and strengthening our financial foundation,” while emphasizing Q3 kit sales “represent nearly 800,000
Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.